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The p53 tumor suppressor pathway coordinates DNA repair, cell-cycle arrest, apoptosis, 
and senescence to preserve genomic stability and prevent tumor formation. The discovery 
of three new target genes for p53 reveals unexpected functions for this tumor suppressor 
in the regulation of glucose metabolism and autophagy.Life is fire—at least aerobic life is. 
Mitochondria consume oxygen and 
burn metabolites to provide chemi-
cal power to cells, and the avail-
ability of nutrients and oxygen are 
important constraints on the growth 
of cells and tissues. However, many 
tumors toss these constraints aside 
in their rush to proliferate and to 
form metastases, gorging on sugar 
and using glycolysis as their major 
energy pathway (Warburg, 1956). 
But how do cells switch from a life 
of moderation to one of gluttony en 
route to oncogenesis? One way may 
be to mutate the tumor suppressor 
protein p53. In response to cellular 
stressors such as oncogene activa-
tion or DNA damage, wild-type p53 
becomes stabilized and switches 
on the expression of target genes. 
These target genes drive a variety of 
cellular responses to stress including 30 Cell 126, July 14, 2006 ©2006 ElsevierDNA repair, cell-cycle arrest, senes-
cence, and apoptosis. Several new 
studies—two published in this issue 
of Cell (Bensaad et al., 2006; Crigh-
ton et al., 2006) and one published in 
a recent issue of Science (Matoba et 
al., 2006)—highlight a new metabolic 
role for p53. This versatile protein not 
only drives damaged cells to undergo 
apoptosis but also coordinates how 
cells use nutrients to preserve their 
survival.
In this issue, Bensaad and col-
leagues (2006) report that p53 plays a 
direct role in cellular metabolism. They 
identify the product of a p53 target 
gene, TIGAR (TP53-induced glycoly-
sis and apoptosis regulator), and show 
that it alters the pathway in which a cell 
uses glucose (see Figure 1). TIGAR 
shares functional sequence similari-
ties with the bisphosphatase domain 
(FBPase-2) of the bifunctional enzyme  Inc.PFK-2/FBPase-2 (6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase), 
which degrades fructose-2,6-bisphos-
phate (Fru-2,6-P2). Fru-2,6-P2 stimu-
lates 6-phospho-1-kinase to convert 
fructose-6-phosphate to fructose-1,6-
bisphosphate at the third step in gly-
colysis; when Fru-2,6-P2 decreases, 
the formation of fructose-6-phosphate 
is favored. Similarly, TIGAR causes 
a decline in Fru-2,6-P2 levels and 
thereby blocks glycolysis at this step, 
directing the pathway into the pentose 
phosphate shunt to produce NADPH 
(see Figure 1).
As the authors note, one conse-
quence of the pentose phosphate 
shunt and increased NADPH gen-
eration is an increase in glutath-
ione (GSH) levels, which promote 
the scavenging of reactive oxygen 
species (ROS). Indeed, the inves-
tigators found that expression of Figure 1. The Myriad Functions of p53
The p53 tumor suppressor pathway coordinates multiple functions to promote genomic stability and to prevent the formation of tumors. The p53 
target DRAM may regulate autophagy by participating in the fusion of the autophagosome with the lysosome. The pathways responsible for glucose 
metabolism and mitochondrial respiration are regulated by the p53 targets, TIGAR and SCO2, respectively. TIGAR blocks glycolysis thus promoting 
activity of the pentose phosphate shunt. SCO2 may enhance oxygen consumption and mitochondrial respiration by regulating the assembly of cy-
tochrome c oxidase (COX). As is the case for glycolysis, mitochondrial respiration and autophagy are controlled by metabolism. A molecular circuit 
may exist that links these three processes to ensure cell survival. The p53 protein can also engage apoptosis by inducing expression of PUMA, 
which leads to release of cytochrome c from mitochondria and apoptosis of the cell. (p53 target genes, red; dotted arrows indicate pathways that 
promote the pentose phosphate shunt.)
TIGAR protected cells from ROS 
and moderately protected cells 
from DNA damage-induced apop-
tosis (although the extent to which 
the latter involves ROS is uncertain). 
Other findings support a model in 
which p53 target genes preserve 
genomic stability by decreasing 
the oxidation of DNA (Sablina et al., 
2005). In addition, cells that have a 
bias toward the pentose phosphate 
shunt may have improved DNA 
repair (Zhang et al., 2003). Intrigu-
ingly, NADPH blocks activation of 
caspase-2 (Nutt et al., 2005), which 
may partly mediate p53-induced 
apoptosis in some cells through 
expression of the p53 target, PIDD. 
However, the extent to which p53-
mediated apoptosis proceeds 
through caspase-2 is unclear. Most 
p53-induced apoptosis depends on 
expression of the p53 target pro-
tein, PUMA, a proapoptotic BCL-2 
family protein (Jeffers et al., 2003). 
Currently, we do not know whether 
NADPH or the pentose phosphate 
shunt affects the function of p53 
or its target genes, directly or indi-
rectly (Figure 1).
Is the predominant role of TIGAR 
to block apoptosis? More than serv-
ing to increase GSH levels, TIGAR’s 
most important role may be to direct 
glucose away from energy produc-
tion and toward the synthesis of 
nucleotides and other products that 
might be important for the repair 
of DNA lesions. Indeed, at least 
one other p53 target gene, p53R2, 
appears to be involved in regulat-
ing nucleotide pools within dam-
aged cells (Tanaka et al., 2000). 
Although the pentose phosphate 
shunt can produce downstream 
products for glycolysis, it is likely 
that a decrease in Fru-2,6-P2 tends 
to shift the pathway toward fruc-
tose-1-phosphate and away from 
energy production. But if this is so, 
how does the cell fulfill its metabolic 
demand for energy? Another recent 
study (Matoba et al., 2006) suggests 
how this may be accomplished. The 
p53 protein induces production of 
a copper transporter, SCO2 (syn-
thesis of cytochrome c oxidase 2), 
which participates in the assembly of cytochrome c oxidase (COX) in 
mitochondria (Matoba et al., 2006). 
Cells lacking p53 have diminished 
oxygen consumption, which could 
be restored by ectopic expression 
of SCO2. Remarkably, mice lack-
ing p53 were much more prone to 
fatigue than wild-type animals, sug-
gesting that p53 performs this func-
tion in the absence of appreciable 
cellular stress.
This finding in primary cells and in 
mice, for what appears to be a non-
tumor-suppressive role for p53, raises 
the question of what induces p53 
function and subsequent metabolic 
changes during day-to-day cellular 
activities. Under conditions where 
mitochondrial oxygen consumption 
becomes faulty, ROS may be gener-
ated resulting in activation of p53 to 
halt glycolysis (thus restricting the 
fuel to drive transfer of electrons to 
molecular oxygen). The action of p53 
via TIGAR also provides NADPH to 
increase GSH levels that are needed 
to scavenge ROS; this feeds back to 
stop the damage signals, presum-
ably while DNA repair intermediates 
are maintained. Meanwhile, during 
oncogenesis, all of these steps are 
bypassed because in cells that accu-
mulate defects in the p53 pathway, 
glycolysis proceeds at full steam 
and the normal restraints on tumor 
growth are lost.
In a related paper in this issue, 
Crighton et al. (2006) provide evi-
dence for another unexpected 
function of p53: involvement in the 
autophagy pathway. They show that 
the p53 target, DRAM (damage-
regulated autophagy modulator), 
engages autophagy, a conserved 
lysosomal-mediated catabolic path-
way involved in the turnover of long-
lived proteins and organelles (Lum 
et al., 2005). DRAM is a lysosomal 
protein with six membrane-span-
ning regions. Its exogenous expres-
sion leads to the accumulation of 
autophagosomes, whereas RNAi-
mediated knockdown of DRAM 
prevents the p53-mediated accre-
tion of autophagosomes (Figure 1). 
Remarkably, knockdown of DRAM 
also preserves clonogenic survival 
of cells treated with a DNA-dam-Cell 12aging agent. The authors provide 
evidence that DRAM is required for 
p53-induced apoptosis and suggest 
that DRAM-dependent autophagy 
acts upstream of cytochrome c 
release from mitochondria and is 
required for apoptosis to proceed.
Autophagy has received much 
attention recently, but there is still 
confusion about whether autophagy 
is exclusively a mechanism for cell 
survival when nutrients are limiting, 
or whether, under some conditions, 
it causes nonapoptotic cell death 
referred to as “autophagic” or “type 
2” cell death. Intriguingly, type 2 
cell death induced by chloroquine 
in some cell types is p53 dependent 
(Zaidi et al., 2001), and we specu-
late that DRAM may be involved in 
this process. Crighton et al. (2006) 
suggest that autophagy operates 
upstream of apoptosis and provide 
evidence that knockdown of an ele-
ment in the autophagic pathway, 
ATG5, prevents apoptosis induced 
by p53. It will be important to elu-
cidate whether this knockdown can 
preserve clonogenic survival of 
DNA-damaged cells, as shown for 
knockdown of DRAM. Curiously, 
another study suggests that knock-
down of ATG5 can itself induce 
apoptosis (Boya et al., 2005). The 
resolution may lie in the actual effect 
of DRAM. The authors propose that 
DRAM induces autophagy, but it is 
also possible that DRAM interferes 
with autophagy at a later stage, 
as is consistent with its localiza-
tion. Such late-stage inhibition of 
autophagy would lead to the accu-
mulation of autophagosomes (as 
the authors observed), thereby 
preventing the cell from gaining a 
catabolic benefit from autophagy, a 
condition that could be lethal.
Collectively, these observations 
suggest that the effects of p53 on 
metabolism are responses to envi-
ronmental conditions. Are these 
effects such that, in some circum-
stances, p53 promotes cell viability 
by regulating metabolism and repair 
pathways that are distinct from its 
control of apoptosis? This possibil-
ity is certainly something to ruminate 
about.6, July 14, 2006 ©2006 Elsevier Inc. 31
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